Abstract 1524P
Background
Gynecological sarcomas (GS) are orphan diseases associated with poor prognosis. With the aim to improve our understanding of GS, the German registry for gynecological sarcoma (REGSA) prospectively recorded patients’ data with GS treated in real-life clinical practice at initial diagnosis and relapse. We present demographic and epidemiological data of patients with GS at the time of initial diagnosis.
Methods
An exploratory analysis among 389 patients (enrolled 2015 - 2021) with different histological subtypes of GS was performed and patients’ data were compared to data of the healthy standard population.
Results
389 patients with GS were descriptively evaluated. Leiomyosarcoma (LMS) was the most common histological subtype (47.3%), followed by low-grade endometrial stromal sarcoma (LG-ESS; 17.7%), high-grade ESS (HG-ESS; 10.4%), adenosarcoma (AS; 9.1%) and undifferentiated uterine sarcoma (UUS; 6.2%). Overall, 9.4% of all GS were classified as “other” rarer subtypes. The mean age of patients was 57.4 years (range: 19-88). There were no statistically significant differences in average age at initial diagnosis nor in BMI among patients with different histological subtypes. In contrast, compared to the standard population, the BMI of patients with GS was significantly higher (27.5 kg/m2 vs 25.1 kg/m2, p<0.001). Most of patients had ECOG performance status 0 (68.3%). REGSA patients were less likely to be smokers compared to the national average of German women (13.4% vs 18.6%). Hypertension was the most common comorbidity as observed in 33.2% of all cases, followed by thyroid diseases (18.6%). The prevalence of hypertension in the German female standard population is approximately 30% and approximately every third person will be affected by thyroid diseases in their lifetime.
Conclusions
The BMI of patients with GS was significantly higher compared to that of the standard population, but REGSA data showed no statistically significant differences in terms of demographic variables between different histological subtypes of GS. Further research is needed to specify risk factors of GS in order to promote primary prevention of this fatal disease.
Clinical trial identification
Deutsche Prospektive Registerstudie zur Erfassung der Behandlungspraxis von gynäkologischen Sarkomen in der klinischen Routine - REGSA Projekt der Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) und der AGO Studiengruppe der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Protokollnummer des Sponsors: NOGGO RU1, Version 1.1 DRKS-ID: DRKS00009240.
Editorial acknowledgement
Mr. Adan Tanovic at PharmaMar for language proofreading.
Legal entity responsible for the study
Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V. - NOGGO e.V.
Funding
PharmaMar, Novartis.
Disclosure
A. Noack: Financial Interests, Personal, Stocks/Shares: AbbVie ; Financial Interests, Personal, Full or part-time Employment: RHEACELL GmbH & Co. KG. D. Zocholl: Financial Interests, Personal, Other, Travel/accomodation/Expenses: Merck Group. S. Kommoss: Financial Interests, Personal, Other, Honoraria: Roche, GSK, MSD, AstraZeneca, Clovis; Financial Interests, Personal, Advisory Role: Roche, GSK, MSD. P. Harter: Financial Interests, Personal, Advisory Board, Value includes honoraria for lectures: AstraZeneca; Financial Interests, Personal, Advisory Board, includes honoraria for lectures: GSK, Roche, MSD; Financial Interests, Personal, Invited Speaker: Amgen, Stryker, Zailab; Financial Interests, Personal, Advisory Board: Clovis, Immunogen; Financial Interests, Personal, Other, IDMC member: Sotio; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Roche, GSK, Genmab, Immunogen; Financial Interests, Institutional, Funding: Seagen, Clovis. E.K. Egger: Financial Interests, Personal and Institutional, Expert Testimony: MSD; Financial Interests, , Other, Travel/Accommodation/Expenses: MSD. P. Buderath: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Roche; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: MSD, PharmaMar. C. Marth: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche Austria, Novartis, MSD, PharmaMar, GlaxoSmithKline, Amgen, Seagen; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, GlaxoSmithKline, Novartis, Amgen, MSD, PharmaMar, Seagen. U. Ulrich: Financial Interests, Personal, Invited Speaker: Stiftung Endometrioseforschung, Arbeitsgemeinschaft Kinder- und Jugendgynäkologie der DGGG; Financial Interests, Personal, Leadership Role: Arbeitsgemeinschaft Gynäkologische Endoskopie der DGGG; Financial Interests, Personal, Research Grant: ECLAT Study, SHAPE Study; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Arbeitsgemeinschaft Gynäkologische Endoskopie, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe . M. Klar: Financial Interests, Personal, Other, Honoraria: KLS martin, Intuitive. M. Weigel: Financial Interests, Personal and Institutional, Other, Honoraria: Roche, GSK, AstraZeneca, Lilly, Novartis; Financial Interests, Institutional, Other, Honoraria: Daiichi-Sankyo, Pfizer, Riemser, Exact Sciences, MSD. L. Traub: Financial Interests, Personal and Institutional, Advisory Role: Roche. L. Hanker: Financial Interests, Personal, Advisory Board: Amgen, Roche, GSK, MSD, Astra Zeneca. M. Pölcher: Financial Interests, Personal, Other, Honoraria: MSD, AstraZeneca, TEVA, Clovis, GSK, Roche; Financial Interests, Personal, Advisory Role: MSD, AstraZeneca, TEVA, Clovis, GSK, Roche. P. Wimberger: Financial Interests, Personal and Institutional, Advisory Board: AMGEN, MSD, AstraZeneca, Novartis, Pfizer, Lilly, Roche, TEVA, Eisai, Clovis, GSK; Financial Interests, Personal and Institutional, Research Grant: Amgen, MSD, AstraZeneca, Novartis, Pfizer, Roche, Clovis, GSK; Financial Interests, Personal and Institutional, Invited Speaker: Amgen, MSD, AstraZeneca, Novartis, Pfizer, Lilly, Roche, TEVA, Eisai, Clovis, GSK. K. Pietzner: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Roche, Tesaro/GSK, Novartis, MSD Sharp&Dome; Financial Interests, Personal, Advisory Board: AstraZeneca, Roche; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: AstraZeneca, Roche, Tesaro/GSK; Financial Interests, Personal, Advisory Role: Tesaro/GSK, MSD Sharp & Dome. J. Sehouli: Financial Interests, Personal, Advisory Board: Roche, GSK, Astra Zeneca, MSD, Tesaro; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Institutional, Funding: Roche, GSK, Astra Zeneca; Financial Interests, Institutional, Invited Speaker: Novocure; Non-Financial Interests, Institutional, Proprietary Information: ENGOT/NOGGO; Non-Financial Interests, , Leadership Role, Council Member: ESGO. All other authors have declared no conflicts of interest.